Navigation Links
ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
Date:8/6/2009

EXTON, Pa., Aug. 6 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that dosing has begun in the Phase 1 clinical trial for NTCD (non-toxigenic Clostridium difficile), a novel treatment approach for preventing recurrent Clostridium difficile infections (CDI). NTCD contains the spores of a non-toxin producing strain of C. difficile.

"Colonization of the large bowel with non-toxin producing strains of C. difficile is known to prevent the development of symptomatic CDI," commented Dr. Colin Broom, ViroPharma's chief scientific officer. "We have the opportunity with NTCD to develop this preventative therapy to significantly reduce the incidence of recurrent disease for patients with CDI. The ultimate goal is to colonize patients with this particular strain of non-toxin producing C. difficile thereby protecting patients until normal GI flora returns."

The Phase 1 study will determine the safety and tolerability of NTCD dosed orally as single and repeat escalating doses in healthy young (18-45 years of age) and older (60 years of age and older) adults. The study is being conducted in Switzerland. Should the therapy be well tolerated, the company plans to initiate NTCD repeat dosing in older adults following exposure to oral antibiotics. Antibiotic use is associated with disruption of gastrointestinal flora which renders individuals susceptible to C. difficile colonization. The goal of NTCD dosing following antibiotic exposure is to colonize with this non-toxigenic strain of C. difficile and to prevent colonization by toxigenic strains, thereby preventing disease.

"NTCD is a novel live-organism biotherapeutic approach to restoring bacterial production against CDI that has been disrupted by antibiotic treatment," state
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... An article published June ... how innovation and technology would be the “key factors” in the growth of ... accessibility and affordability, especially in emerging and growing markets. According to the compounding ...
(Date:7/7/2015)... BELLINGHAM, WA (PRWEB) , ... July 07, 2015 , ... ... set to break ground as early as Summer 2015 on a four-acre site in ... dollar project, with the support of city officials and other members of the local ...
(Date:7/7/2015)... , ... July 07, 2015 ... ... convenience stores throughout the Southwest, including Giant, Mustang, Sun Dial and Howdy’s, ... program, surpassing their original 2015 fundraising goal by nearly $100,000, to help ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... ... Times highlights rumors about possible facial rejuvenation that have emerged about Hillary Clinton. ... U.S. Secretary of State looks more youthful than she has in some time ...
(Date:7/7/2015)... ... July 07, 2015 , ... Quadrino Law Group is pleased to announce the ... York 11747. The new facility is a state of the art building, located ... Quadrino, the firm's CEO and founder, said, "We are pleased to service our clients ...
Breaking Medicine News(10 mins):Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 2Health News:Recent Article on Pharmaceutical Innovation Highlights the Need for Creative Solutions to Common Problems, Says Medlife Pharmacy 3Health News:New Silverado Memory Care Community Receives Unanimous Approval from Design Review Board 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 2Health News:Western Refining Raises $524,286 to Help Send Kids with Neuromuscular Disease to MDA Summer Camp 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3
... of the Phase 2,clinical trial of R788 (fostamatinib ... lymphoma (NHL) will be presented today at a,plenary ... Hematology (ASH),Meeting. The results affirm preliminary reports ... patients and shows therapeutic benefit in,patients suffering from ...
... weight, instead of dieting, is a good way to keep ... News) -- The holiday season is always extra challenging for ... in the fun without packing on the pounds. , ... Brigham and Women,s Hospital in Boston, recommends trying to simply ...
... December 7, 2008) The largest study ever to ... prevent deadly blood clots in patients with cancer undergoing ... on Sunday, December 7, at 9:30 a.m., during the ... in San Francisco, CA. Additional research being featured at ...
... (SAN FRANCISCO, December 6, 2008) A study assessing the ... a variety of hospital settings will be presented at a ... the 50th Annual Meeting of the American Society of Hematology ... that help determine stroke risk in children with sickle cell ...
... The United States can learn from the Dutch Health Insurance ... Ph.D., in the December issue of the Journal of ... management, policy and community health at The University of Texas ... which discusses universal health care coverage in the Netherlands and ...
... create partnerships with pediatric research institutions around the globe, ... understanding with the department of pediatrics at Tokyo,s Jikei ... the first among Mattel Children,s Hospital,s many planned agreements ... , Signed last month, the UCLAJikei ...
Cached Medicine News:Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 2Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 3Health News:Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL 4Health News:Holidays Don't Have to Make You Heavier 2Health News:Research highlights new approaches to prevent blood clots 2Health News:Research highlights new approaches to prevent blood clots 3Health News:Research highlights new approaches to prevent blood clots 4Health News:Research highlights new approaches to prevent blood clots 5Health News:Research highlights new approaches to prevent blood clots 6Health News:Research highlights new approaches to prevent blood clots 7Health News:Research highlights new approaches to prevent blood clots 8Health News:Studies examine quality of care for hospitalized sickle cell disease patients 2Health News:Studies examine quality of care for hospitalized sickle cell disease patients 3Health News:Studies examine quality of care for hospitalized sickle cell disease patients 4Health News:Studies examine quality of care for hospitalized sickle cell disease patients 5Health News:Studies examine quality of care for hospitalized sickle cell disease patients 6Health News:Studies examine quality of care for hospitalized sickle cell disease patients 7Health News:Studies examine quality of care for hospitalized sickle cell disease patients 8Health News:UT public health policy expert says US can learn from Dutch universal healthcare coverage 2
(Date:7/7/2015)... July 7, 2015 BioRx, a Diplomat company (NYSE: ... a Top Workplace in 2015 based on a survey held ... Media Group and a Philadelphia -based research ... and was completed by employees across the Greater ... area, with topics ranging from workplace environment to overall organizational ...
(Date:7/7/2015)... 7, 2015 Hill-Rom,s recent announcement that ... in cash and stock means the company can ... to Kalorama Information. The healthcare market researcher said ... device and advanced wound care markets, and is ... lifting devices, and other healthcare equipment. Welch Allyn,s ...
(Date:7/7/2015)... --  ICD-10 Charts ( www.icd10charts.com ) announced today ... officially launched its newest line of ICD-10 preparation ... new 4 Step ICD-10 Implementation Plan.  Both of ... Charts resources and mobile apps, are available to ... the release of these resources, the company has ...
Breaking Medicine Technology:BioRx Named a Top Workplace in 2015 by Enquirer Media 2BioRx Named a Top Workplace in 2015 by Enquirer Media 3Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 2Kalorama: Hill-Rom Enters Monitoring Market with Welch Allyn Purchase 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4
... WIRE)--May 15, 2007 - Synthetic Blood,International, Inc. ... analysis of its Phase IIa study with ... line with preliminary,study results announced in December ... of increasing patients' oxygen,tension levels compared with ...
... WIRE)--May 17, 2007 - Salix,Pharmaceuticals, Ltd. (NASDAQ:SLXP) today ... the Company's products,will be presented at Digestive Disease ... Digestive Disease Week is considered the,largest and most ... Every year it attracts more than 16,000 physicians,researchers ...
Cached Medicine Technology:Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 2Positive Statistical Analysis from Synthetic Blood's Oxycyte,Traumatic Brain Injury Trial Indicates Achievement of Primary,Endpoint 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 2Salix Pharmaceuticals Previews Digestive Disease Week 2007 3Salix Pharmaceuticals Previews Digestive Disease Week 2007 4Salix Pharmaceuticals Previews Digestive Disease Week 2007 5
Curved, 6.0 mm tying platforms, with pin, extra delicate smooth jaws., ,Curved, extra delicate tips, smooth jaws....
Angled, 7.5 mm tying platforms.,Titanium, 111 mm long, 6 mm tying platforms....
Gerl tying forceps, titanium, with 0.12 mm teeth....
Microsurgical curved forceps made of titanium has curved shafts with smooth working surface. TCI working parts 6 mm from tips with round handle, diam. 6 mm, overall length 116 mm....
Medicine Products: